TrialGynecologic oncology2017

Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.

Nicole D Fleming et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.